Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Item
http://www.wikidata.org/entity/Q34974068
Long-term follow-up after purine analogue therapy in hairy cell leukaemiaCurrent and emerging treatment options for hairy cell leukemiaTargeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaIrreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia.Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese.[Hemato-oncological diseases].Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.How I treat hairy cell leukemia.Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Update on the biology and treatment options for hairy cell leukemia.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients.Impact of telomere length on survival in classic and variant hairy cell leukemia.Immunoconjugates in the management of hairy cell leukemia.My treatment approach to hairy cell leukemia.Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.Hairy cell leukemia - immunotargets and therapiesLong-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option.Combination therapies to improve the long-term outcome in hairy cell leukemia.Long-term follow-up studies in hairy cell leukemia.Hairy cell leukemia: short review, today's recommendations and outlook.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis.Chemo-immunotherapy for hairy cell leukemia.Purine analog toxicity in patients with hairy cell leukemia.Insight into the behavior of hairy cell leukemia by immunogenetic analysis.Development of cladribine at Scripps for hairy cell leukemia and current results.Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.Hairy cell leukaemia: biological and clinical overview from immunogenetic insights.Hairy cell leukemia-new genes, new targets.Hairy cell leukemia: a 'hair-raising' update.Novel therapeutic options for relapsed hairy cell leukemia.
P2860
Q26776327-B91D1C73-3442-4745-9E0D-6068F363E24CQ26796423-C99AC390-E477-4C2A-8DE4-86F1513589C4Q27853209-3724663C-5D20-41BD-8E3A-4CEE23AFB55AQ30391711-B5CF9230-75E8-4D37-8B27-816CE5BDE745Q33396744-A377C0EB-4788-4059-BBB8-DBA1DC71CB70Q33410075-4EDBAA55-2BCA-4CF0-A824-E7B555F61C52Q33410756-6E688FEC-B968-408A-80EA-9F0D80C1C134Q33579506-68157810-03AA-4395-BE83-029AF9C4BF94Q33782644-95BBA8A2-E391-4978-AFBB-870E3A839AC9Q33844299-3136EE0E-EB7C-4A0F-BF1F-47118E05B575Q33854868-BAF1F828-7827-44B9-A8CD-A427DD99216EQ33924158-723963D9-6EF7-49CB-9302-ED9E624CB464Q34343369-CE0BAD4D-07C3-482B-AE50-EC98A36B54AFQ34387911-FF618D0E-D55A-4DFF-A1F0-B442B6CF6E16Q34459751-5C4F2020-35C3-4491-A8EC-6FA9D0F1C553Q36058502-6C79354D-C859-48DA-8CC2-305F6C7728E3Q36208306-96AC8FCB-E11B-4BAF-8376-95E9245D9C95Q36322450-944876A4-AC3A-4705-A1F7-C7CAB75AE46AQ36328016-35C650EE-7CB4-400C-B909-FA22A97E3695Q36399120-4C837C8D-0A9D-4F9D-B1BE-2794B6E6D55DQ36768594-2E01A327-FD8D-4C89-A030-C455483970DEQ36799737-579138D2-E1C6-4D26-B132-8A223D9785A6Q37031666-A392483C-4384-4D3F-86AF-E9BE876B6F1DQ37043067-D9C50273-FCD5-43C5-B4B9-07D1509A83E4Q37611073-2515D11F-19F2-4F2D-ABE8-88FC20FA0C70Q37611075-3A36D549-FD24-48EF-9E1A-9D718D72A645Q37621357-2E28D996-55D0-43D6-8B05-51FD2A0CE264Q37623386-91B3E7B9-0563-474C-8C20-F9E8AB53052EQ37816419-EF5AB15E-CC2A-4EE7-A0C0-56DE4EA8C9C4Q37854692-8F3D32F9-4961-4E10-BBE9-0A1E3C3A5C2EQ37861187-CC66D0BD-7543-4476-897A-CF54273BD77EQ37866773-D287E413-99B5-4E3B-A4BB-27C7A4AF64FEQ37866776-8359B862-6066-4B8C-9DCD-AC781EC474EFQ37877736-DD7C21A1-52A5-423E-8542-2F57B1562E2BQ37877737-F1BA2C66-1A6F-43E8-84B1-A6707C928542Q37877743-54A6CC60-5A50-4D19-B873-D85D93FC1090Q37889776-805A5B71-2D7D-4ECA-BB77-B183E01E26C8Q38124726-72A963CF-7F99-476C-8460-87044511042BQ38242304-5408B575-97B9-47CA-B2C9-D0937C0A43C0Q38308974-FFBD95C5-4EAF-4EFA-A065-DA57DBA2C28E
P2860

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Item
http://www.wikidata.org/entity/Q34974068
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@ast
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@en
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@nl
type
label
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@ast
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@en
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@nl
prefLabel
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@ast
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@en
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Long-term follow-up of 233 pat ...... an of 16 years from diagnosis.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2141.2009.07668.X
P407
P433
P478
P50
P577
P5875
P698
P921